636P Tucatinib and trastuzumab in advanced cancers with HER2 mutations or amplification: A molecular screening and therapeutics (MoST) program substudyBenjamin Y. Kong, David Goldstein, D. Espinoza et al.|Annals of Oncology|2024Cited by 0